Who Paid My Doc
Robin Goland
Endocrinology, Diabetes & Metabolism New York, NY
NPI 1174549760 CMS profile 908841
1150 Saint Nicholas Ave, 2Nd Fl, New York, NY 10032
General payments
$0
Research payments
$0
Ownership & investment interest
$0
The CMS Open Payments record contains no reported payments to Robin Goland of New York, NY.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
Prescribing to Medicare patients
Part D · data year 2024 · 18 drugsPart D claims
477
Drug cost
$225,107
Branded share of claims
85.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jardiance Empagliflozin | Brand | 51 | $44,041 | |
| Mounjaro Tirzepatide | Brand | 21 | $33,779 | |
| Ozempic Semaglutide | Brand | 22 | $28,379 | |
| Trulicity Dulaglutide | Brand | 13 | $21,947 | |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | Brand | 34 | $16,696 | |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 82 | $14,274 | |
| Humalog Insulin Lispro | Brand | 27 | $11,451 | |
| Tresiba Flextouch U-100 Insulin Degludec | Brand | 12 | $11,040 | |
| Insulin Lispro Kwikpen U-100 Insulin Lispro | Brand | 13 | $9,016 | |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | Brand | 35 | $8,311 |
The 10 drugs with the highest cost, of 18 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 10 billing codesPaid by Medicare
$11,363
Medicare patients
45
Services billed
195
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Diabetes | 75% | |
| High blood pressure | 73% | |
| Arthritis | 42% | |
| Osteoporosis | 31% | |
| Ischemic heart disease | 29% | |
| Chronic kidney disease | 29% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Other Endocrinology, Diabetes & Metabolism in New York
Robert Busch
Endocrinology, Diabetes & Metabolism · Albany, NY
Michael Shanik
Endocrinology, Diabetes & Metabolism · Smithtown, NY
Ajay Chaudhuri
Endocrinology, Diabetes & Metabolism · Buffalo, NY
Vinay Kapoor
Endocrinology, Diabetes & Metabolism · Manhasset, NY
John Bilezikian
Endocrinology, Diabetes & Metabolism · New York, NY
Barbara Hirsch
Endocrinology, Diabetes & Metabolism · Manhasset, NY
Related records
Endocrinology, Diabetes & Metabolism in New York
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.